HGF/c-MET Pathway in AIDS-Related Lymphoma
Abstract
During the whole funding period (2015-2018), we have completed all the 3 Specific Aims as listed in the SOW forms above. Our results have illuminated the complicated mechanisms through which the HGF/c-MET pathway regulates KSHV+ PEL cell survival. Our exciting in vivo data have provided the framework for development and implementation of clinical trials for evaluating strategies targeting HGF/c-MET (alone or combination of other therapies) for the treatment of lymphoma in HIV-infected patients including military personnel. Until January 2019, we have totally published 25 peer-reviewed articles about the molecular mechanisms of KSHV viral oncogenesis, and developing novel therapeutic strategies against these malignancies. In most of these publications, I am served as the corresponding or co-corresponding author. We also have published 9 meeting abstracts on national or international meetings. With the support by this DOD award, I have obtained several intramural and extramural funding, including a NIH/NCI RO1 funding (as PI) and a NIH COBRE subproject (as the project leader).
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2019
- Accession Number
- AD1095139
Entities
People
- Zhiqiang Qin
Organizations
- LSU Health Sciences Center New Orleans